The National Institutes of Health (NIH) has announced over $150 million in funding to accelerate the development of human-based research methods and reduce reliance on animal models. This initiative, launched under the Complement Animal Research in Experimentation (Complement-ARIE) program, focuses on advancing new approach methodologies (NAMs), including lab-based and computational systems that better replicate human biology.
The program will establish technology development centers to drive innovation in key disease areas such as neurological, cardiac, gynecological, and rare conditions. Supporting infrastructure includes a centralized data hub for standardization and a validation network built through public-private partnerships to ensure regulatory readiness.
Additional efforts include pilot projects targeting preterm birth and toxicology, alongside a $7 million challenge co-led with the U.S. Food and Drug Administration and Environmental Protection Agency to accelerate real-world application. Together, these initiatives aim to improve translational success and expand the scientific toolkit for human-relevant research.
Read more:
Lambda Biologics’ Organoid Solutions: Advancing Ethical Science, Together
Drug development demands accuracy, speed, and relevance to human biology. At Lambda Biologics, we deliver advanced organoid-based platforms that replicate the complexity of human organs – empowering pharmaceutical and biotechnology companies to make better decisions, faster.
Cerebral Organoid | Midbrain Organoid | Skin & Hair Organoid | Intestine Organoid |
